2026-08-11 | Computational Evaluation of Dabogratinib and C-Type Natriuretic Peptide Analogue Co-treatment in Achondroplasia
Achondroplasia is usually caused by an overactive form of FGFR3, a receptor that normally slows bone growth. Dabogratinib (TYRA-300) blocks FGFR3, while C-type natriuretic peptide (CNP) analogues act further down the same signalling network. This computer study asked whether combining these two approaches could restore growth-plate signalling better than either approach alone. Four ordinary differential equations represented active FGFR3, CNP-driven cGMP/PKG signalling, MAPK/ERK and STAT1. Two further outputs represented cell proliferation and matrix/differentiation. A 21 × 21 grid tested 441 pairs of normalised treatment intensities. Combination effects were measured with Bliss independence and highest-single-agent (HSA) scores. The untreated disease state lowered the proliferation index from 1.000 to 0.563. The strongest qualifying pair was T = 0.20 for dabogratinib and C = 0.30 for the CNP analogue. Its Bliss score was 0.216 and its HSA score was 0.457. Eighty-one pairs met the study's synergy rule, 360 were approximately additive and none were antagonistic. In 3,000 tests with varied parameter values, 97.2% of samples still met the synergy rule. At high intensities, the result became additive because the output had already reached its upper limit. These findings support an intermediate-intensity synergy hypothesis within the model. They do not prove that the drug combination is safe or effective in people. Laboratory data are needed to test and improve the model.
Open article ↗
2026-08-09 | Longitudinal growth pattern of Hungarian children with achondroplasia: The evaluation of treatment-related growth changes
Background: Achondroplasia is characterized by a distinctive growth pattern involving disproportionate short stature, limb shortening, macrocephaly and altered growth velocities throughout childhood. Objective: The project aims to examine the impact of vosoritide (VOXZOGO®) treatment on growth patterns in children with achondroplasia and to assess the applicability of the European achondroplasia-specific growth references to a Hungarian achondroplasia cohort. Subjects and methods: The longitudinal study was initiated in October 2025. To date, 20 Hungarian children with achondroplasia, aged 2–13 years, have been enrolled at the Department of Paediatrics, Semmelweis University, Budapest, Hungary. Anthropometric assessments are conducted at baseline and repeated at 3‑month intervals throughout the follow-up period. Measurements include body weight, body height/length, sitting height, arm span, lengths of the upper and lower limb segments, trunk and limb circumferences and breadths, as well as head dimensions. The observed growth patterns are evaluated relative to the growth channels defined by the European achondroplasia-specific reference standards. Results: In this pilot study, analyses focused on body weight, body height/length, body mass index and head circumference. The preliminary findings demonstrate the applicability of the European achondroplasia-specific reference standards for monitoring individual growth trajectories. At this preliminary stage, the analyses focus on determining whether the observed growth patterns remained within or deviated from the growth channels of the achondroplasia-specific references. Conclusion: Our newly developed anthropometric protocol provides a standardized framework for the longitudinal assessment of growth in children with achondroplasia and includes an extensive set of body and head measurements that enable detailed monitoring of body proportions and cranial growth throughout childhood. Extended follow-up will be required to clarify the influence of vosoritide treatment on the overall growth patterns of children with achondroplasia.
Open article ↗
2026-07-17 | Genetic Bone Diseases: A Scoping Review of Pathology, Symptoms, Diagnosis, Treatment, and New Horizons.
Genetic bone diseases are a rare group of afflictions suffered by the general population. However, their rarity should not diminish research efforts to help patients understand and treat their diseases. This review summarizes the pathology, symptoms, diagnosis, and treatment insight into six well-known genetic bone diseases. Only six bone diseases are included due to the relatively low prevalence of them as whole limiting our scope to ensure accurate information and attention is provided for each disease individually. A literature search of PubMed is conducted, including studies published within the past five years (January 2020-December 2025). Thirty-six studies met inclusion criteria, and no significant risk of bias is identified among the selected articles. Study findings are synthesized into disease overview, clinical and radiographic features, and diagnostic and treatment approaches. Actively developing or novel therapies relevant to each disease are also included. These treatments include: fresolimumab for osteogenesis imperfecta, small interfering ribonucleic acid (RNA) therapy for Osteopetrosis, denosumab for Paget's disease of bone, vosoritide/recifercept/infigratinib for achondroplasia, mesenchymal stem cell therapy for craniosynostosis, and combination losartan and atenolol therapy for Marfan syndrome. These treatments are generally more recently acknowledged in literature and are either actively undergoing research or require further research to determine their efficacy.
Open article ↗
2026-06-25 | Second drug approved for achondroplasia
Navepegritide (Yuviwel), a C-type natriuretic peptide analog, is the second drug to be approved for the treatment of achondroplasia. It is administered subcutaneously once weekly. The retail cost for navepegritide is expected to be almost half a million dollars annually.
Open article ↗
2026-06-03 | Navepegritide: First Approval.
Navepegritide (YUVIWEL®) is a prodrug of C-type natriuretic peptide (CNP) developed by Ascendis Pharma for the treatment of achondroplasia and is being investigated for hypochondroplasia. Navepegritide is administered once weekly and designed to provide sustained release and continuous exposure of active CNP, which is needed to counteract the overactive fibroblast growth factor receptor 3 signaling in achondroplasia, resulting in improved growth velocity. Navepegritide recently received accelerated approval in the USA for increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.
Open article ↗
